Filing Details
- Accession Number:
- 0001192482-21-000094
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2021-01-22 16:05:24
- Reporting Period:
- 2021-01-19
- Accepted Time:
- 2021-01-22 16:05:24
- Original Submission Date:
- 2021-01-21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1267565 | Collegium Pharmaceutical Inc | COLL | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1734919 | R. Shirley Kuhlmann | C/O Collegium Pharmaceutical, Inc. 100 Technology Center Drive Stoughton MA 02072 | Evp And General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-01-19 | 45,360 | $0.00 | 102,891 | No | 4 | A | Direct | |
Common Stock | Acquisiton | 2021-01-19 | 6,772 | $0.00 | 109,663 | No | 4 | A | Direct | |
Common Stock | Disposition | 2021-01-20 | 6,081 | $24.45 | 103,582 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | A | Direct | |
No | 4 | S | Direct |
Footnotes
- Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.
- On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 6,772 performance share units granted in two prior years.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.